Fosdesdenosine sipalabenamide
![]() | |
| Clinical data | |
|---|---|
| Other names | NUC-7738 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C26H29N6O7P |
| Molar mass | 568.527 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Fosdesdenosine sipalabenamide is an investigational new drug that is being evaluated for the treatment of advanced solid tumors and lymphoma.[1] This compound is a phosphoramidate derivative of cordycepin (3'-deoxyadenosine), a chemical compound originally isolated from the fungus Cordyceps militaris.[2][3] As a nucleoside analog with potential antineoplastic properties, Fosdesdenosine sipalabenamide is designed to inhibit RNA synthesis and act as an RNA inhibitor.[1] The drug is being developed by NuCana Plc.[1]
References
- 1 2 3 "Fosdesdenosine sipalabenamide". PatSnap.
- ↑ "Fosdesdenosine Sipalabenamide". PubChem. U.S. National Library of Medicine.
- ↑ Serpi M, Ferrari V, McGuigan C, Ghazaly E, Pepper C (December 2022). "Synthesis and Characterization of NUC-7738, an Aryloxy Phosphoramidate of 3'-Deoxyadenosine, as a Potential Anticancer Agent". Journal of Medicinal Chemistry. 65 (23): 15789–15804. doi:10.1021/acs.jmedchem.2c01348. PMC 9743095. PMID 36417756.
